Amonafide: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 01:28, 6 August 2011 editCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'DrugBank_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology\|erro← Previous edit		Latest revision as of 13:39, 20 January 2024 edit undoMaxim Masiutin (talk \| contribs)Extended confirmed users, IP block exemptions, Pending changes reviewers31,058 edits Altered title. Added s2cid. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors.
(21 intermediate revisions by 15 users not shown)
Line 1:		Line 1:
			{{Short description\|Chemical compound}}
	{{drugbox
			{{cs1 config\|name-list-style=vanc}}
⚫	\| ~~Verifiedfields~~ = changed
			{{Drugbox
⚫	\| UNII_Ref = {{fdacite\|~~changed~~\|FDA}}
		⚫	\| Watchedfields = changed
⚫	\| UNII = 1Q8D39N37L
	\| verifiedrevid = ~~403349247~~		\| verifiedrevid = 443275125
	\| IUPAC_name = 5-amino-2--1''H''-benzoisoquinoline-1,3(2''H'')-dione		\| IUPAC_name = 5-amino-2--1''H''-benzoisoquinoline-1,3(2''H'')-dione
	\| image = Amonafide.svg		\| image = Amonafide.svg

			<!--Clinical data-->
			\| tradename = Xanafide, Quinamed
		⚫	\| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
		⚫	\| pregnancy_US = <!-- A / B / C / D / X -->
		⚫	\| pregnancy_category =
		⚫	\| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
		⚫	\| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
		⚫	\| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
		⚫	\| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
		⚫	\| legal_status =
		⚫	\| routes_of_administration =

			<!--Pharmacokinetic data-->
		⚫	\| bioavailability =
		⚫	\| protein_bound =
		⚫	\| metabolism =
		⚫	\| elimination_half-life =
		⚫	\| excretion =

			<!--Identifiers-->
		⚫	\| CAS_number = 69408-81-7
		⚫	\| ATC_prefix = none
		⚫	\| ATC_suffix =
		⚫	\| PubChem = 50515
		⚫	\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}
		⚫	\| DrugBank =
	\| ChemSpiderID_Ref = {{chemspidercite\|correct\|chemspider}}		\| ChemSpiderID_Ref = {{chemspidercite\|correct\|chemspider}}
	\| ChemSpiderID = 45804		\| ChemSpiderID = 45804
		⚫	\| UNII_Ref = {{fdacite\|correct\|FDA}}
		⚫	\| UNII = 1Q8D39N37L
		⚫	\| ChEMBL_Ref = {{ebicite\|correct\|EBI}}
		⚫	\| ChEMBL = 428676
			\| KEGG_Ref = {{keggcite\|correct\|kegg}}
			\| KEGG = D10090

			<!--Chemical data-->
		⚫	\| C=16 \| H=17 \| N=3 \| O=3
		⚫	\| smiles = O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
	\| StdInChI_Ref = {{stdinchicite\|correct\|chemspider}}		\| StdInChI_Ref = {{stdinchicite\|correct\|chemspider}}
	\| StdInChI = 1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3		\| StdInChI = 1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3
	\| StdInChIKey_Ref = {{stdinchicite\|correct\|chemspider}}		\| StdInChIKey_Ref = {{stdinchicite\|correct\|chemspider}}
	\| StdInChIKey = UPALIKSFLSVKIS-UHFFFAOYSA-N		\| StdInChIKey = UPALIKSFLSVKIS-UHFFFAOYSA-N
⚫	\| smiles = O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
⚫	\| CAS_number = 69408-81-7
⚫	\| ChEMBL_Ref = {{ebicite\|correct\|EBI}}
⚫	\| ChEMBL = 428676
⚫	\| ATC_prefix = none
⚫	\| ATC_suffix =
⚫	\| PubChem = 50515
⚫	\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}
⚫	\| DrugBank =
⚫	\| C=16\|H=17\|N=3\|O=3
	\| molecular_weight = 283.325 g/mol
⚫	\| bioavailability =
⚫	\| protein_bound =
⚫	\| metabolism =
⚫	\| elimination_half-life =
⚫	\| excretion =
⚫	\| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫	\| pregnancy_US = <!-- A / B / C / D / X -->
⚫	\| pregnancy_category=
⚫	\| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
⚫	\| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫	\| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
⚫	\| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫	\| legal_status =
⚫	\| routes_of_administration =
	}}		}}
	'''Amonafide''' (originally AS1413) (], trade ~~name~~ '''Quinamed''') is a drug that is being studied in the treatment of ]. It belongs to ~~the~~ ~~families~~ of drugs called ]s and ]s.		'''Amonafide''' (originally AS1413) (], trade names '''Quinamed''' and '''Xanafide''') was a drug that was being studied in the treatment of ]. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential ] and ].<ref name="Allen_2011">{{cite journal \| vauthors = Allen SL, Lundberg AS \| title = Amonafide: a potential role in treating acute myeloid leukemia \| journal = Expert Opinion on Investigational Drugs \| volume = 20 \| issue = 7 \| pages = 995–1003 \| date = July 2011 \| pmid = 21591994 \| doi = 10.1517/13543784.2011.585756 \| s2cid = 10999582 }}</ref><ref name="Freeman_2012">{{cite journal \| vauthors = Freeman CL, Swords R, Giles FJ \| title = Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia? \| journal = Expert Review of Hematology \| volume = 5 \| issue = 1 \| pages = 17–26 \| date = February 2012 \| pmid = 22272701 \| doi = 10.1586/ehm.11.68 \| s2cid = 26740617 }}</ref>

	It is being developed as an anti-cancer therapy by ].<ref>http://www.genengnews.com/news/bnitem.aspx?name=78979622 </ref>		It was being developed as an anti-cancer therapy by ].<ref>{{cite web \| title = Antisoma's Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial \| url = http://www.genengnews.com/news/bnitem.aspx?name=78979622 \| archive-url = https://web.archive.org/web/20100401235144/http://www.genengnews.com/news/bnitem.aspx?name=78979622 \| archive-date = 1 April 2010 \| date = 29 March 2010 \| work = Genetic Engineering & Biotechnology News }}</ref>

	{{As of\|2008}}, it is in ] ]s.		{{As of\|2008}}, it is in ] ]s.
	eg In March 2010 it is ] trial against secondary ] (AML).<ref>~~http://clinicaltrials.gov/ct2/show/~~NCT00715637 "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study"</ref>		e.g. In March 2010 it is ] trial against secondary ] (AML).<ref>{{ClinicalTrialsGov\|NCT00715637\|Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study}}</ref> In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.{{cn\|date=February 2023}}

			==See also==
			* ]

	==References==		==References==
Line 49:		Line 64:

	== External links ==		== External links ==
	* entry in the public domain NCI Dictionary of Cancer Terms		* entry in the public domain NCI Dictionary of Cancer Terms
	* at ClinicalTrials.gov		* at ClinicalTrials.gov

Latest revision as of 13:39, 20 January 2024

Chemical compound

Pharmaceutical compound

Amonafide
Clinical data

Trade names	Xanafide, Quinamed
ATC code	none
Identifiers
IUPAC name 5-amino-2--1H-benzoisoquinoline-1,3(2H)-dione
CAS Number	69408-81-7
PubChem CID	50515
ChemSpider	45804
UNII	1Q8D39N37L
KEGG	D10090
ChEMBL	ChEMBL428676
CompTox Dashboard (EPA)	DTXSID30219562
Chemical and physical data
Formula	C₁₆H₁₇N₃O₃
Molar mass	299.330 g·mol
3D model (JSmol)	Interactive image
SMILES O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
InChI InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3 Key:UPALIKSFLSVKIS-UHFFFAOYSA-N
(verify)

Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.

It was being developed as an anti-cancer therapy by Antisoma.

As of 2008, it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML). In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.

References

Allen SL, Lundberg AS (July 2011). "Amonafide: a potential role in treating acute myeloid leukemia". Expert Opinion on Investigational Drugs. 20 (7): 995–1003. doi:10.1517/13543784.2011.585756. PMID 21591994. S2CID 10999582.
Freeman CL, Swords R, Giles FJ (February 2012). "Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?". Expert Review of Hematology. 5 (1): 17–26. doi:10.1586/ehm.11.68. PMID 22272701. S2CID 26740617.
"Antisoma's Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial". Genetic Engineering & Biotechnology News. 29 March 2010. Archived from the original on 1 April 2010.
Clinical trial number NCT00715637 for "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study" at ClinicalTrials.gov

External links

Amonafide entry in the public domain NCI Dictionary of Cancer Terms
Clinical trials of amonafide at ClinicalTrials.gov

This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories:

Latest revision as of 13:39, 20 January 2024

See also

References

External links